Odisha News, Odisha Latest news, Odisha Daily - OrissaPOST
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
No Result
View All Result
OrissaPOST - Odisha Latest news, English Daily -
No Result
View All Result

DCGI allows Biophore India to manufacture coronavirus drug Favipiravir API

PTI
Updated: July 14th, 2020, 18:33 IST
in Sci-Tech
0
Share on FacebookShare on TwitterShare on WhatsAppShare on Linkedin

Hyderabad: Biophore India Pharmaceuticals, a Hyderabad-based firm, has received license from the Drug Controller General of India (DCGI) to manufacture Favipiravir, an active pharmaceutical ingredient (API), used in the finished formulation to treat mild to moderate COVID-19 cases.

https://www.orissapost.com/tag/coronavirus/

Also Read

Pakistan gas pipeline network

Saudi firm signs $30 billion deal with Pakistan for gas pipeline network

1 day ago

Apple unveils revamped ‘Maps’ in India with Look Around, 3D landmarks

1 day ago

Besides DCGI’s nod to produce the drug in India, it has been cleared for exports as well.

It also received approval in Turkey to export the API in collaboration with a local partner and additionally, the company is in talks with several Indian partners to commercialize the product in India and with Bangladesh and Egypt-based companies for its export, Biophore India said.

“The Covid-19 pandemic has emphasized the need for pharmaceutical companies to step up and develop effective solutions quickly, without compromising on safety.

We have ensured that our favipiravir meets the highest standards of quality,” Founder and Chief Scientific Officer (CSO) of Biophore, Manik Reddy Pullagurla said.

“Our manufacturing facilities comply with US and EU regulations and we have stringent internal impurity controls and quality checks to ensure that.

Meeting favipiravir needs in India is our priority, and we have the capacity to scale up production to meet local requirements, without compromising on our export commitments,” he said.

Favipiravir is an antiviral agent that was initially discovered and developed because of its activity against another RNA (ribonucleic acid) virus, the influenza virus.

Apart from India and Turkey, it has already been approved for use against COVID-19 in Russia and parts of the Middle East while advanced stage trials are currently underway in other parts of the world.

CEO of Biophore, Jagadeesh Babu Rangisetty said all starting materials and complex intermediates for making favipiravir are either sourced locally or have been developed in-house for use.

“We are confident that this API will help our country move several steps forward in our united fight against Covid-19,”Jagadeesh Babu said.

Biophore is also awaiting DCGI approval for a favipiravir finished dosage form.

(PTI)

Tags: Biophore IndiaCOVID-19DCGIFavipiravir
ShareTweetSendShare
Suggest A Correction

Enter your email to get our daily news in your inbox.

 

OrissaPOST epaper Sunday POST OrissaPOST epaper

Click Here: Plastic Free Odisha

#MyPaperBagChallenge

Rajashree Manasa Mohanty

December 12, 2019
#MyPaperBagChallenge

Lopali Pattnaik

December 12, 2019
#MyPaperBagChallenge

Tapaswini Mallick

December 12, 2019
#MyPaperBagChallenge

Akriti Negi

December 12, 2019
#MyPaperBagChallenge

Anup Mahapatra

December 12, 2019
#MyPaperBagChallenge

Adyasha Priyadarsani Sendha

December 12, 2019
#MyPaperBagChallenge

Narendra Kumar

December 12, 2019
#MyPaperBagChallenge

Geetanjali Patro

December 12, 2019
#MyPaperBagChallenge

Amritansh Mishra

December 12, 2019
#MyPaperBagChallenge

Subhajyoti Mohanty

December 12, 2019
#MyPaperBagChallenge

D Rama Rao

December 12, 2019
#MyPaperBagChallenge

Saishree Satyarupa

December 12, 2019
#MyPaperBagChallenge

Archit Mohapatra

December 12, 2019
#MyPaperBagChallenge

Ramakanta Sahoo

December 12, 2019
#MyPaperBagChallenge

Mrutyunjaya Behera

December 12, 2019
#MyPaperBagChallenge

Smitarani Sahoo

December 12, 2019
#MyPaperBagChallenge

Sipra Mishra

December 12, 2019
#MyPaperBagChallenge

Diptiranjan Biswal

December 12, 2019
#MyPaperBagChallenge

Pitabas Tripathy

December 12, 2019
#MyPaperBagChallenge

Sarmistha Nayak

December 12, 2019
#MyPaperBagChallenge

Kamana Singh

December 12, 2019
#MyPaperBagChallenge

Sitakanta Mohanty

December 12, 2019
#MyPaperBagChallenge

Shreyanshu Bal

December 12, 2019
#MyPaperBagChallenge

Jhili Jena

December 12, 2019
#MyPaperBagChallenge

Anasuya Sahoo

December 12, 2019
#MyPaperBagChallenge

Nishikant Rout

December 12, 2019
#MyPaperBagChallenge

Adrita Bhattacharya

December 12, 2019
#MyPaperBagChallenge

Jyotshna Mayee Pattnaik

December 12, 2019
#MyPaperBagChallenge

Keshab Chandra Rout

December 12, 2019
#MyPaperBagChallenge

Manas Samanta

December 12, 2019

Archives

Editorial

Tech Terror

November 18, 2026

It cannot be a coincidence that when the world was still trying to come to terms with the prospect of...

Read moreDetails

More Miseries Ahead

Inflation in India
November 17, 2026

Life is getting difficult by the day for Indians with all us citizens reeling under the dual shocks of rising...

Read moreDetails

Tough Times

Press
November 16, 2026

Press freedom has, for years, been under attack almost everywhere across the globe, but the situation has never been as...

Read moreDetails

Democracy Strikes Back

Rights & Restrictions: AAKAR PATEL
November 15, 2026

By Aakar Patel Democracies correct themselves through elections. The leadership of every nation is imperfect, and the problems become especially...

Read moreDetails
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Editorial
  • Opinion
  • Sports
  • About Us
  • Advertise
  • Contact Us
  • Jobs
Developed By Ratna Technology

© 2025 All rights Reserved by OrissaPOST

  • News in Odia
  • Orissa POST Epaper
  • Video
  • Home
  • Trending
  • Metro
  • State
  • Odisha Special
  • National
  • International
  • Sports
  • Business
  • Editorial
  • Entertainment
  • Horoscope
  • Careers
  • Feature
  • Today’s Pic
  • Opinion
  • Sci-Tech
  • About Us
  • Contact Us
  • Jobs

© 2025 All rights Reserved by OrissaPOST

    • News in Odia
    • Orissa POST Epaper
    • Video
    • Home
    • Trending
    • Metro
    • State
    • Odisha Special
    • National
    • International
    • Sports
    • Business
    • Editorial
    • Entertainment
    • Horoscope
    • Careers
    • Feature
    • Today’s Pic
    • Opinion
    • Sci-Tech
    • About Us
    • Contact Us
    • Jobs

    © 2025 All rights Reserved by OrissaPOST